Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 28, 2017
Pharmacy Choice - Pharmaceutical News - Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma - June 28, 2017

Pharmacy News Article

 5/19/17 - Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma

SAN CARLOS, CA (Marketwired) 05/19/17 Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in the second cohort of its ongoing Phase 2 trial of LN-144 for the treatment of patients with metastatic melanoma. This cohort utilizes the company's generation 2 manufacturing process which includes cryopreservation of the outbound products.

"We are pleased to be able to offer a shorter manufacturing process for TIL to the melanoma patients enrolling in Cohort 2 of LN-144 trial. This process reduces the time from excision to infusion from approximately six weeks to just over three weeks and includes cryopreservation for the outbound product," said Maria Fardis, PhD, MBA, Lion Biotechnologies President and Chief Executive Officer. "Reducing the time from excision to infusion is critical for treatment of advanced melanoma patients. This process provides greater flexibility for physicians and patients in scheduling the time of the infusion due to the cryopreserved nature of the TIL product. Further, the shorter process increases the manufacturing flexibility for Lion leading to lower production costs."

This Phase 2, multicenter, three-cohort study will assess the safety and efficacy of LN-144 for treatment of patients with metastatic melanoma. Cohorts one and two will enroll 20 patients each and cohort three is a re-treatment cohort for a second LN-144 infusion in ten patients. Lion Biotechnologies will be releasing interim data from the first cohort of this study at the upcoming 2017 American Society of Clinical Oncology Annual Meeting from June 2-6 in Chicago, IL. For additional information on this study please go click on the link below:

https://www.clinicaltrials.gov/ct2/show/NCT02360579?term=ln-144&rank=1

About Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with refractory metastatic melanoma, metastatic squamous cell carcinoma of the head and neck, and metastatic cervical carcinoma. For more information, please visit http://www.lionbio.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including risks related to the Company's ability to increase its manufacturing capacity and throughput, decrease manufacturing costs and other risks described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

   Investor Relations Contact: Sarah McCabeStern Investor Relations, Inc.212-362-1200sarah@sternir.com Media Relations Contact:Evan Smith/Kotaro YoshidaFTI Consulting212-850-5622/212-850-5690 evan.smith@fticonsulting.comkotaro.yoshida@fticonsulting.com

Source: Lion Biotechnologies, Inc.




Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jun 28: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Last Chance
Jun 29: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Jul 02: HIV Medications: Newer Drugs, Newer Guidelines
Jul 03: Management of Major Depressive Disorders
Jul 05: Medication Safety & Drug Safety Alerts
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415